

In the article “Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents” by Dan W. Haupt, M.D., et al. (published online January 15, 2009; doi: 10.1176/appi.ajp.2008.08030383), the guideline periods in the last sentence of the first paragraph of the Results section “Metabolic Testing Rates (Univariate Analysis)” should be transposed so that the sentence reads “Glucose monitoring rates were higher than lipid monitoring rates, baseline monitoring rates were higher than week 12 rates, and there was a small increase in the proportion of patients who were monitored for metabolic effects in the post- versus preguideline periods.” This change has been made for the article’s print appearance in the March 2009 issue and for its online posting as part of that issue, replacing the article posted January 15.